Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
More News
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings?
ANIP trades at 9.75x forward earnings after raising 2026 guidance, but investors must weigh Cortrophin-led growth against competition and customer concentration.
Zacks
ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push
ANIP expands Cortrophin into acute gout flares with a 90-person sales force as investors watch adoption, spending and 2026 milestones.
Zacks
ANIP Pharmaceuticals' Cortrophin Gel Drives 2026 Growth
ANIP bets on Cortrophin Gel to power 2026 growth as rare disease sales become the majority of revenues. What must keep working?
Zacks
Why ANI Pharmaceuticals (ANIP) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence.
Zacks
ANIP Valuation: Does 9.8x Forward P/E Offer Upside?
ANI Pharmaceuticals trades at 9.83x forward earnings, far below peers and its five-year median despite rising Rare Disease sales.
Cortrophin Gel is reshaping ANI Pharmaceuticals into a specialty-driven growth story, with 2026 revenue guidance signaling another major leap.
Zacks
ANI Pharmaceuticals (ANIP) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million
Key PointsSold 228,895 shares of ANI Pharmaceuticals; estimated trade value $17.87 million (based on average Q1 2026 pricing...